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Abstract
It is amazing to see how medical science has progressed. Medical research is now cross-
national and cross-cultural, the relentless progress of globalization poses complex ethical 
questions for those wishing to do medical research in developing countries. In develop-
ing countries, poverty, endemic diseases, and a low level of investment in health care sys-
tems influence both the ease of performing and the selection of trials that can benefit the 
people of the countries. In this chapter, we present an overview of medical research situ-
ation in developing countries with critique of different clinical trials that was conducted 
in Egypt after review. Egypt has 41 universities and 94 health related medical schools. 
There are 24 faculties of medicine with up to 34 departments in each. Clinical research is 
an essential mandate for getting Master, Doctorate Degrees, and for promotion of faculty 
members. In Egypt, the Profession Ethics Regulations issued by the Ministry of Health 
(MOH) No. 238/2003 was endorsed and maintained in Law 71/2009. Beside these regula-
tions, more than 56 Institutional Review Board (IRB) have been registered. The Egyptian 
Network of Research Ethics Committees (ENREC) was created in 2008. Yet, in the absence 
of robust legislative constraints, there is no clear way to avoid violations. Our experience 
in Tanta Faculty of Medicine is also highlighted in this chapter.
Keywords: medical research, medical ethics, developing countries, Egypt, Tanta Faculty 
of Medicine, Tanta REC
1. Introduction
It is amazing to see how medical science has progressed. It has only been a hundred years and 
the world has gone from the discovery of penicillin to the complete sequencing of the human 
genome. This is the “Medical Research.”
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Many researches are driven by economic or academic interests that may or may not reflect the 
needs of the host country. One critic of such trials is the need to test new drugs for malaria, 
sleeping sickness, and Chagas disease that people in poor countries suffer from rather than on 
diseases of interest primarily to the developed nations.
There is also the delicate matter of double standards, which highlights the need to develop 
an ethical model for research and training partnerships between developed and developing 
countries employing an approach with long-term advantage for the latter or both partners at 
least in an equal manner.
2. Realities of medical research in developing countries
2.1. Historical background
The past 20 years have seen a considerable shift in the location of clinical drug trials spon-
sored by transnational pharmaceutical companies (TNCs) being conducted in low- and mid-
dle-income settings [1]. One of the primary obligations of the Declaration of Helsinki (DH) is 
to promote human well-being over the interest of science and society. According to DH, any 
medical study should provide every participant with the best proven diagnostic and thera-
peutic method [2]. The primary ethical commitment would be obtaining rapid, nonargued 
answers that may make researchers cross the line that forbids treating human subjects as 
a means to an end, leaving nothing to protect patients from underestimating their dignity, 
rights, and safety for the sake of research goals [3].
One of the great challenges in medical research is to conduct clinical trials in developing coun-
tries that benefit the citizens of these countries. After the textbook example of the unethical 
40-year nontherapeutic study of 400 African American sharecroppers in “the Tuskegee Study 
of Untreated Syphilis” (TSUS), ethical concern stood on its head and led to the overhauling 
of federal guidelines for health research [4]. These reforms, however, do not extend to health 
studies conducted outside the United States [5].
Ethical review committees are present in developing countries in the form of research institutes 
or other scientific panels [6]. However, the reality is that these panels need to be independent 
and able to review clinical trials without prejudice. Also, the characteristics of many develop-
ing countries, which include population afflicted with life-threatening endemic diseases, pov-
erty, and a low level of investment in health care systems, affect both the ease of performing 
trials and the selection of trials that can benefit the populations of the countries. Conflict of 
interest of physicians/researchers from developing countries is a detrimental factor in research 
bias. There are also some structural problems including the fact that operations of pharma-
ceutical research companies are not adequately controlled or authorities seem unwilling to 
address unethical drug testing [7].
There appears to be a general retreat from the clear principles enunciated in the Nuremberg 
Code and the DH as applied to research in the third world. Angell in 1997 wondered, “Why 
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is that?!!” He attributed it to the differences in local standard of care or variation in diseases 
and their treatments in those regions, so that information gained in the industrialized world 
has no relevance making it a must to start from scratch [3].
2.2. International situation in developing countries
Indeed, the scale of the problem is unknown, because it cannot be estimated how many uneth-
ical clinical trials escape public attention and therefore remain unnoticed. Starting in 1996, 
TSUS-like scenario occurred in Pfizer’s controversial Trovan clinical trials that took place in 
Kano over 200 persons, mostly children [8]. The new quinolone was tested without parents’ 
informed consents; patients were unaware of the experiment and without an ethical review 
committee’s approval of the trial in advance. Out of 190 children that were enrolled in the 
trial, five receiving the drug died while others suffered brain damage and paralysis. A panel 
of Nigerian medical experts reported that the trials had been illegal and exploitative and 
violated Nigerian law, the DH, and the UN Convention on the Rights of the Child. However, 
Pfizer denied that the drug trial was unethical [9].
One of the major examples of the Tuskegee-like trials in the third world is the regimens to 
prevent the vertical transmission of human immunodeficiency virus (HIV) [10]. According 
to CDC, 18 randomized, controlled trials of interventions to prevent perinatal HIV transmis-
sion were identified until 1997, 16 were conducted in developing countries in Côte d’Ivoire, 
Uganda, Tanzania, South Africa, Malawi, Thailand, Ethiopia, Burkina Faso, Zimbabwe, Kenya, 
and the Dominican Republic [11].
These trials involved a total of more than 17,000 women. In 15 of these trials, some or all of the 
patients were not provided with clearly effective zidovudine antiretroviral drug as they employ 
placebo-treated control groups. Failures to get patients’ consent about changes in the experi-
ment, administering wrong doses, serious problems in record keeping, delayed and under-
reporting of fatal and life-threatening problems, nondiscloser of thousands of side effects and 
adverse reactions, not following procedures for divulging Serious Adverse Events (SAEs), and 
destroying an early copy of the research reports are part of the violation of guidelines [10, 12].
Another same example was the dramatic Cariporide clinical trial applied in the Naval Hospital 
in Buenos Aires, Argentina to protect against heart damage after cardiac insult. Patients’ con-
sents were either faked or the patients did not know its contents. Thirteen patients died and at 
least three of them were considered murders. Data in medical records were changed and key 
documentation disappeared [13]. Although before 2005, the Schedule Y of the Indian Drug 
and Cosmetic Act prohibited clinical trials in India of drugs developed outside the coun-
try before Phase II trials were completed abroad, a review revealed that some illegal stud-
ies were conducted in 1999–2000. Phase III trials involving cilansetron, a new molecule of 
Solvay Pharmaceuticals for treatment for diarrhea from irritable bowel syndrome (IBS) [14], 
Pfizer’s zoniporide trial that control perioperative cardiac events [15], nordihydroguaiaretic 
acid (NDGA) as treatment for oral cancer, and Otsuka’s cilostazol trials for treatment of inter-
mittent claudication were tested before the required animal experiments had been completed 
and serious adverse events were not reported [15, 16].
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Between 2002 and 2006, the number of trials to compare antiretroviral standard continuous and 
intermittent therapies was conducted in Africa. The Development of Anti-Retroviral Therapy 
(DART) trial had recruited 3300 volunteers in Uganda and Zimbabwe [17]. Unfortunately, 
unethical trials continue to be conducted. One recent trial in India, reported in The Lancet in 2014, 
evaluated human-bovine (116E) vaccine for preventing a very common, potentially life-threat-
ening viral infection “rotavirus” [18]. Two rotavirus vaccines have been available for the past 
decades that were proved to be highly effective in preventing rotavirus-induced gastroenteritis 
and the need for hospitalization. One of the unfair examples, despite the availability of these 
vaccines, more than 2000 children in the Indian trial received placebo injections of salt water 
rather than one of the available effective vaccines in a clinical trial funded by multiple private 
and government sources and enrolled approximately 6800 infants between 2011 and 2012 [18].
The central ethical question should be: why has not the successful intervention that is cur-
rently used as a matter of course in Western countries become the standard of care worldwide? 
Clinical trials have become a big business with many studies done in developing countries, 
as it is necessary to do quick work with minimal obstacles. Poverty and ignorance play a role 
in commercial industry like this. This does not suit the standards of the sponsoring countries 
and puts us not very far from Tuskegee even after more than 80 years [19]. This is a big con-
cern for all of human race. Like Lurie and Wolfe [10], we need to redouble our commitment 
to the highest ethical standards, no matter where the research is conducted, and sponsoring 
agencies need to enforce those standards, not undercut them.
2.3. The case of Egypt: strength versus weakness
The contract research organization (CRO) Quintiles even recently advertised Russia, Turkey, 
and the Middle East and the Northern Africa MENA region as the “new darlings” in the 
world of biopharmaceutical sales [20]. According to the ClinicalTrial.gov, a service of the 
U.S. National Institute of Health (NIH), 1234 clinical trials were conducted in Egypt with 
the number of clinical trials nearly tripling between 2008 and 2011 making Egypt second 
only to South Africa on the African continent in terms of the number of TNC-sponsored 
studies [21, 22]. Based on the registry of clinical trials (CTs) in Egypt, treatment was the 
most common study purpose followed by prevention. Combined safety/efficacy was the 
most common endpoint followed by efficacy alone. For interventional studies, the most 
common intervention was drug use followed by procedure. The most common study phase 
was phase 3 followed phase 4 and phase 2. However, the output of the big number of health 
professionals and faculty members is definitely more than the registered studies, which, 
may be related to absence of Egyptian national trial registry and the national mandates for 
trial registration [23].
In February 2016, 21 international pharmaceutical and biotechnology companies were sponsor-
ing active drug trials in Egypt. The two Swiss giants Novartis and Roche carried out the lion’s 
share of trials. These trials took place at 131 sites spread over 9 cities in Egypt. Unsurprisingly, 
the majority was in Cairo (75), followed by Alexandria (31)—together accounting for about 
81% of all sites. Over half of all international active drug studies in Egypt are cancer trials, fol-
lowed far behind by infectious diseases (10%) and metabolic disorders (10%) [21].
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An attractive research infrastructure, a fast-growing and largely treatment-naïve popula-
tion, a mosaic panel of research areas, and incomparably low cost of living make Egypt 
among the most popular places in the MENA region for off-shoring medicine testing 
“pharmerging countries” [24]. Egypt has 41 universities and 94 health-related faculties and 
medical schools. There are 24 faculties of medicine with up to 34 departments in each 
faculty. There are more than 42,000 faculty members and 344,000 postgraduate students, 
140,000 physicians, 18,200 dentists, 37,500 pharmacists, 176,000 nurses, and 35,000 physi-
cal therapists. Clinical research including clinical trials is an essential mandate for getting 
masters and doctorate degrees. Moreover, clinical research for publication is a mandate for 
promotion for faculty members according to the rules of the supreme council of Egyptian 
universities [23].
According to the Professional Ethics Regulations issued by the Ministry of Health (MOH) 
No. 238/2003, part four: “conducting medical research and experiments on human beings, 
any experiments for drugs and techniques on human beings prior to being endorsed by the 
competent quarters and acquiring a detailed study of the risks/benefits relationship are pro-
hibited.” The volunteers must comply in a clear way of the targets of the research, the research 
approaches, the benefits expected, the probable risks, and the extent of their effect on them 
with official written consent and/or approval of the official guardian or curator in the pres-
ence of a prosecution witness. The volunteers have the right to cease or withdraw from the 
research without sustaining any negative consequences. The researcher is required to submit 
a detailed and clear research targets report with justifications for conducting it on human 
beings to the approving authority for approval [25]. The same meaning was maintained in 
Law 71/2009 and a new draft law of 2014 [26, 27]. However, this draft caused much public 
concern because it contained an article allowing trials on children, pregnant women, drug 
addicts, detainees, and psychiatric patients. According to critics, it would have paved the way 
to experimentation of medicines on vulnerable people. Thus, this law has never seen the light 
of day [27].
The researcher is expected to discontinue any experiments on human beings if the accom-
panying risks exceed the benefits expected of the research and ensuring all preventive, diag-
nostic, and therapeutic methods for each patient for conducting the study. The draft of the 
national law on clinical trials driven from the constitution of Egypt that was leaked to the 
media in 2014 tried to lift those safeguards [27].
Besides these regulations, more than 56 RECs and Institutional Review Board (IRB) registered 
were designed in many health-related faculties, foundations, and institutes in Alexandria, 
Assuit, Aswan, BeniSuif, Benha, Fayoum, Giza, Ismailia, Mansoura, Minia, Sohag, Tanta, and 
Zagazig. Egyptian Network of Research Ethics Committees (ENREC) was created in 2008 to 
raise the harmonization between Research Ethics Committees, facilitate more uniform ethical 
review, and simplify REC procedures and standards [6].
Since there is no robust legislative constraints and clear guidance to charge entities or stake-
holders involved in overseeing or executing clinical trials, concerns are increasingly being 
raised, whether ethical pitfalls of clinical research are adequately addressed, and whether the 
safety and the rights of subjects are constantly prioritized and maintained, leaving room for 
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different interpretations and making it more difficult to identify violations and impose sanc-
tions [28, 29]. Unlike other emerging countries, Egypt does not make it obligatory to have clini-
cal trials conducted on their population before marketing approval is granted [30]. Moreover, 
there are concerns that RECs in Egypt may not be able to provide high standards of human 
subjects’ protection due to its inadequate functioning ethics review system and reluctance of 
the national regulations and bureaucracy that occurs when they interact with the MOH [22, 31].
An extensive review carried out by multiorganizations, published in June 2016 and based 
on United Nation International Aid Program (UNIAID), Egyptian experts and clinical trial 
participants’ interviewee and various media reports, many critics were assumed. Although 
they admit that the current requirements of Egypt’s regulatory authorities that no clinical 
trial sponsored by a TNC can be conducted in Egypt unless the product being tested has 
been granted market approval in the originating country with several Egyptian experts inter-
viewed during this research confirmed this prerequisite, they pointed to the absence of regu-
latory obligation to conduct clinical trials in the country before being able to request a license 
for the drug. This “conditional approval” may happen based on medical grounds such as 
genetic or disease specificities prevailing in Egypt [22].
Of the 57 international drug trials that were active in Egypt in February 2016, Declaration 
of Helsinki concluded that the vast majority are late-stage clinical trials related to prod-
ucts already licensed in high-income countries. However, 16% are Phase I and Phase II 
trials, raising ethical issues as to the relevance and benefit of these trials for the Egyptian 
population since tests on these medical products were completed elsewhere for market-
ing approval in a high-income country. These include cancer trials testing medicines that 
were not yet registered in high-income countries, off-label use, had no specific protection 
mechanism for vulnerable participants, and no posttrial treatment access mechanisms. 
International experts raised doubts about the scientific validity of the designs of several of 
these cancer trials [32].
• Kotb in 2012 recounts an incident that was under official investigation. The trials used drug 
ursofalk (ursodeoxycholic acid) that was conducted on children at one of Cairo Univer-
sity’s hospitals, providing evidence that only 9% of the children improved while most of 
the cohort receiving treatment developed hepatic failure, lethal pneumonia, otitis media, 
and ascites with high incidence of death was uncovered [33].
• According to the Declaration of Helsinki Study, cancer trials described in Egypt were con-
sidered to be the clearest illustration of the vulnerability of trial participants and the pro-
found inequality of their situation compared to cancer patients in wealthier nations. Due to 
the high prices of cancer treatments, experimental drugs may be the only medication that 
Egyptian cancer patient will receive. As such, they run an unknown risk of experiencing 
serious side effects while already suffering a serious disease [34].
• Egypt has the highest prevalence of viral hepatitis C in the world and was the first low- or 
middle-income country in 2014 to negotiate preferential pricing for the new direct acting 
antiviral (DAA) treatment sofosbuvir (Sovaldi) with manufacturer Gileadc [35]. However, 
the deal (US$ 300 per month of treatment instead of US$ 84,000 in the U.S.) was criticized 
International Development44
for its opacity. The “Sovaldi deal” generated diverging opinions among Egyptian experts 
as to whether the state-subsidized free treatment program is, in fact, a disguised clinical 
trial of national scale [36]. Given the absence of patent protection, several Egyptian compa-
nies were able to produce generic versions of DAAs for the market [32].
Ethics in health research is a collective consciousness and concerns of researchers, institutes, 
funders, medical journals’ editors, regulatory agencies, and others. Ethical approval by one of 
these entities does not relieve others from responsibility. Egyptian authorities should develop a 
single, robust legislative framework with a functional independent control system that takes the 
DH and the Council for International Organizations of Medical Research (CIOMS) Guidelines 
as their reference point for ethical standards. Egyptian authorities should also create an online, 
regularly updated public registry of clinical trials conducted in Egypt. Ensuring access to infor-
mation must be guaranteed, as it is a fundamental prerequisite to enable civil society to play its 
role in signaling, observing, auditing, and unveiling unethical clinical trials practices.
2.4. Tanta Faculty of Medicine model experience
University hospitals have their own in-house IRBs, which provide training to medical doc-
tors and researchers participating in clinical trials. The only mechanism available to protect 
participants is the REC in the MOH, in the research centers, and in university hospitals [37].
To develop an educational and medical research policy in Tanta Faculty of Medicine, we plan 
the following standards to be on the track of international standards.
2.4.1. Research Ethics Committee
Research Ethics Committee (REC) plays a central role of ethical oversight of research involv-
ing humans or animals in our organization. REC reviews research proposals involving human 
or animal participants to ensure that they are ethically acceptable and in accordance with rel-
evant standards and guidelines. Our REC includes institutional review board members and 
was organized and approved at the Faculty and University levels in June 2010.
In undertaking this role, REC is guided by relevant standards, which include those in the 
International Statement on Ethical Conduct in Human Research issued by CIOMS and WHO 
[38, 39]. Consequently, this Statement identifies the demands, principles, and values by which 
research should be designed and applied and to which HREC should refer when reviewing 
research proposals.
It also sets up requirements and responsibilities for:
• Researchers in submitting research proposals to REC.
• REC in:
(1) Considering and reaching decisions regarding these proposals and in monitoring the con-
duct of approved research plus to monitor and reporting any scientific misconduct.
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(2) Developing awareness and teaching the ethics of scientific research for the faculty post-
graduate and undergraduate students.
(3) Cooperation with the ethics committees of scientific research counterparts in Egypt, the 
Arab, and foreign countries.
2.4.2. Research plan
In general, the educational mission of the Faculties of Medicine is fortified by a highly suc-
cessful research enterprise that includes widely varied scientific fields such as basic molecular 
and cellular biology and population health as well as hospital and community applied clinical 
researches.
Our institution’s goal was to develop a plan to support research excellence in strategic areas, 
train the next generation of health researchers, and facilitate the translation of new knowl-
edge into beneficial health outcomes for the patients, the population, and policy makers. 
Our Faculty has developed and established a strategic research plan in 2010. This plan was 
reviewed and modified according to Tanta University research plan and updated the paths 
proposed by the Ministry of Higher Education, then reapproved in June 2015. These plans 
are the outcome of an institutional planning committee after extensive consultation with all 
faculty departments.
2.5. The settled research priorities and guidelines of the ongoing plan are
Nine health-related areas of high priority were chosen guided by the international standards 
and based on the approved research plan of our university, mission, and vision of our fac-
ulty, needs assessment of the community at local, national and regional levels, interests and 
specialties of our staff members, available research resources including that supplied by sci-
entific and health organizations with mutual interest, and the updates in science and medi-
cine [40].
These research priorities are:
(1) Cancer research: to foster basic as well as clinical research in the field of early diagnosis, 
recent treatment modalities, and prevention.
(2) Emerging national health problems: The epidemiology, health effects, prevention, and 
eradication of emerging national health problems, e.g., hepatitis, H1N1, parasitic, and 
endemic diseases in our country.
(3) Organ transplantation and artificial prostheses.
(4) Obesity researches: causes, treatment, and prevention.
(5) Immunogenetic diseases: our vision is to implement research in biotechnology.
International Development46
(6) Geriatric diseases.
(7) Regenerative medicine and stem cell therapy: Tanta Faculty of Medicine is catching up 
with the research in the area of tissue culture and application of the concept of stem 
therapy in medicine.
(8) Minimal interventional medicine and surgery (MIS).
(9) Emergency medicine.
Our REC has reviewed 2823 research protocols and project proposals in the last 6 years up 
to July 31, 2016. Note that 1705 proposals (60.4%) were accepted while 1118 (39.6%) needed 
modifications with rejection rate of 18% after corrections. The activity of REC has signifi-
cant impact on our research. In 2011, Tanta Faculty of Medicine had about 140 international 
publication cited on PubMed, this number reached 616 at the beginning of 2016 with almost 
threefold increase in 5 years. Additionally, in an attempt to strengthen medical research, we 
established our official medical journal (Tanta Med J) as an online peer-reviewed journal pub-
lished by Wolters Kluwer—Medknow. Since January 30, 2014, more than 200 articles were 
published in it apart from those cited in PubMed.
The REC committee has members from academic and clinical medical departments. They 
are selected based on their experience in different medical fields and their reputation for a 
term of 3 years. To insure its independence, our Faculty Dean and Vice deans were excluded 
from the committee board. The committee members also included representatives of the com-
munity: professor in Islamic religion, representative of the Orthodox Church, governor (or 
his representative), certified trainer in research ethics, certified trainer in human rights, and 
a judge as representative of the legal authority. Clear regulations were approved to support 
the committee’s role. The number of the committee members range from 5 to 15 according 
to its regulations (in the current term there are 13 members), they meet on a monthly basis 
to discuss research proposals and to follow-up on approved projects. The committee pays 
members a very small incentive for each meeting and there are no fees charged for protocol 
review. IRBs face numerous obstacles to achieving their goals, as there is no law in Egypt 
that regulates the selection of members of IRBs. Other problems include budget constraints, 
inability to monitor approved protocols continuously, and a lack of national guidelines and 
accreditation mechanisms for IRBs. These points are our future concern to improve the per-
formance of REC.
3. Background
Poverty accounts for almost one-third of the global burden of disease and there is a definite 
relationship between wealth/poverty and health/disease, although this relationship is not lin-
ear [41]. In “developing” countries, where cultural, linguistic, economic, and other barriers 
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may prevail between researchers and subjects, it is especially important to ensure effective 
communication [42, 43].
The medical industry is not exempted from the development of globalization, and the num-
ber of medical research studies conducted in developing nations, instead of in Western coun-
tries, has rapidly increased to gain more financial and scientific benefits [44, 45].
3.1. Advantages of conducting medical research in developing countries
When the United States’ National Bioethics Advisory Commission (US-NBAC) asked a phar-
maceutical researcher why the industry seeks to conduct studies in developing countries, the 
answer was that the pharmaceutical industry is not a charitable business. It is a profitable 
Wall Street hard-core business [46]. There are several reasons that attract these companies 
to conduct their research in developing countries. Ruth Macklin divides these reasons into 
financial and scientific [45].
From sponsors’ point of view, the main financial reasons are that the speed of research is 
faster in the developing country due to less oversight, thereby enabling the company gain 
approval for marketing and realize a profit sooner [46]. Research can often be done faster in 
those areas as time-consuming legislative requirements and local ethical review committees 
are not as well established in developing countries as in Western countries. Macklin points 
out that financially it is cheaper to carry out research in developing countries as they can offer 
lower costs for all of the ancillary goods and services necessary to set up and support the 
research, including labor costs for technical and scientific personnel [47].
Lack of awareness among participants about the methods and reasoning of research in 
healthcare may lead to therapeutic misconception as participants believe that the main goal 
of research is to provide them with therapy not to obtain information. For this reason, the 
US-NBAC recommended that investigators working overseas must indicate in their research 
protocols how they intend to minimize the possibility of therapeutic fallacy [48, 49].
3.2. Excellence in medical research
Regrettably, 50 years after the Nuremberg trials and the Nuremberg Code, unethical medi-
cal research on humans continues, even in highly privileged countries [50–52]. Similarly, the 
continuation of human and patient rights abuses for 50 years after the Universal Declaration 
of Human Rights, even in wealthy industrialized countries, illustrates how difficult it is to 
achieve such universal moral aspirations [53, 54]. How research be regulated to avoid the 
errors and indiscretions of the past and to avoid new forms of discrimination and victimiza-
tion in the increasingly complex era of biotechnology?
Early in 1993, the Council for International Organizations of Medical Research (CIOMS) 
launched its guidelines endorsing that ethical values must reinforce respect for the dignity of 
research subjects and to minimize risk, maximize benefits, make convenient compensation for 
time, provide reparation for any damage occurring during the research, protect confidential-
ity, and avoid conflict of interest [55–60].
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3.3. Methods to achieve universal standards
Universal ethical standards are still a debatable complex issue, which requires reflection on 
some issues. First, the best interests of subjects that may differ significantly according to per-
sonal and cultural priority and the magnitude of achievement in any situation. Second, what 
is considered truly universal? Third, is the entity of contextual issues that could be considered 
moral without resorting to ethical relativism [61–64]. Among those, recognition and dealing 
with contextual differences is a must to avoid both ethical imperialism and ethical relativism 
[65, 66].
3.4. International ethical guidelines
Different countries have different laws, different views on human rights, and different ethical 
principles. Most countries in the developed world have their own set of laws and regulations 
concerning research with human subjects. These laws and regulations emphasize the key 
principles of human research such as informed consent, risk minimization, reasonable risk-
benefit ratio, and confidentiality [67].
Developing countries may not possess such regulations or if they do, the regulations are 
weaker. Additionally, there are no international laws on medical research that apply in 
all countries to which all researchers conducting studies in another country must follow. 
However, there are international ethical guidelines for conducting medical research that can 
be followed in order to design and conduct an ethical research in a developing country. The 
most widely accepted are the Nuremberg Code, the DH, and the guidelines developed by the 
CIOMS [67].
3.5. Research ethics committees in developing countries
In many developing countries, ethics has been paid insufficient attention. There is minimal 
similarity in the organization of research ethics committees (RECs) and little if any public 
responsibility. Existence of self-appointed private RECs lacking in expertise and liability, the 
absence of rational discourse, and possibilities of undeclared conflict of interest express most 
problems in some countries [59, 60].
3.6. Comprehensive guidelines for research ethics in developing countries
Many categories of issues require special consideration in formulating new guidelines for 
biomedical research on human subjects in “developing” countries. Incommensurable load of 
diseases aggravated by the extent of destitution and high levels of illiteracy is a major issue 
to be considered. Differences between patients’ categories lead to added rights and ethical 
consideration in special groups by age or disease. Imbalance between the needed and actual 
resources available for research and basic health care with wide differences in access to health 
care is another important category. Finally, inadequate scientific and ethics infrastructures for 
the required reviewing process are a key issue [68, 69].
Current Review of Medical Research in Developing Countries: A Case Study from Egypt
http://dx.doi.org/10.5772/67282
49
4. Concept of medical research
4.1. Value of medical research
Research is explained by Health Insurance Portability and Accountability Act (HIPAA) 
including the Privacy Rule and the Common Rule as “a systematic investigation, including 
research development, testing and evaluation, designed to develop or contribute to general-
ized knowledge” [70, 71].
Data analysis collected for either diagnostic or treatment purposes can be used for secondary 
research purposes. These purposes could be health services or public health research that 
include analysis of occurrences’ patterns, determinants, natural history of disease, drug safety 
surveillance, and some genetic and/or social studies [72–74].
4.2. The importance of medical research
Medical research serves as sources of important information about disease outcomes, drift 
and risk factors, functional abilities, patterns of care, and health care costs. Clinical trials are 
sources of important notification about the efficacy and adverse effects of medical interven-
tions by controlling the variables that could influence the study results [73, 74].
Food and Drug Administration (FDA) approval of a drug for a particular indication relies 
upon a series of controlled clinical trials. Guidelines for best practices with high-quality 
patient care can be achieved by recording and assessing experience in clinical practice [75]. 
Economists notice that medical research has a positive effect on human health and life span 
which in turn increase productivity that will be reflected on the national economy [76].
4.3. The globalization of medical research
Medical research goes globalization is a familiar term. Globalization has brought on economic 
benefits such as higher production rates, more efficiency, industrialization, and faster grow-
ing knowledge and innovation for those countries that are a part of it. We hear about poor 
working environment and low salaries in developing countries, a situation that Western com-
panies have taken advantage of, which makes us think that everything that follows is not 
always morally justifiable [77].
The pharmaceutical industry is not exempted from globalization and has embraced it is as 
a core component of their business models, especially in the realm of clinical trials. Industry 
and government sponsors in wealthier countries move their research trials to less wealthy 
countries. The majority of medical research is currently sponsored and conducted by private 
pharmaceutical companies [78].
Medical research proved the fact that globalization of commerce, trade, industry, and travel 
means that diseases can spread easily across the globe. For example, HIV spread from Africa 
and around the world and each year a new strain of the influenza virus emerges in Southeast 
Asia and spreads throughout the globe. As diseases have become international, medical 
research should also become international [77].
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4.4. The value and importance of medical information privacy
Medical privacy and confidentiality are vital to improving human health and health care. 
Protecting patients involved in research from harm or abuse and preserving their rights is 
essential to ethical research. Privacy has a value at the societal level as it permits complex 
activities, including research and public health activities to be carried out in ways that protect 
individuals’ dignity without violating their rights [79].
4.4.1. Value of privacy
Privacy is simply used to designate different concepts as the right to body safety or to be free 
from supervision. All information being gathered, the intentions of the parties involved, as 
well as the politics and cultural probability [80, 81]. Privacy denotes those concerned with 
personal information collection, storage, and examine whether data can be collected either for 
primary or secondary purposes [82].
4.4.2. The importance of privacy
There are a variety of reasons for placing a high value on protecting the privacy, confiden-
tiality, and security of health information [83]. Some theorists believe that respecting pri-
vacy (and autonomy) is a form of recognition of the attributes that give humans their moral 
uniqueness and part of human rights [84, 85].
Privacy facilitates and promotes other fundamental values, including ideals of personhood [86, 87] 
such as:
• Personal autonomy (the ability to make personal decisions)
• Individuality
• Respect
• Dignity and worth as human beings
Perceptions of privacy vary among individuals and various groups. Data that are considered 
intensely private by one person may not be by others [74].
4.5. Distinguish medical research from practice
Privacy rule can differentiate between medical research and similar health care practices as 
public health practice, quality improvement activities, and program evaluations [88] and 
writing reviews [76]. However, specifying which activities meet the definition of “research” 
is a major challenge for privacy boards [89]. Neither the regulations of investigators and 
health care practitioners nor their interpretations by HHS denote clear guidelines on how 
to distinguish research from activities that use similar techniques to analyze health informa-
tion [90]. Unfortunately, failure to correctly denote an activity as research could potentially 
allow improper disclosure of personally identifiable health information without sufficient 
oversight [91].
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4.6. Genetic information and the privacy rule
Research involving genetic information presents perhaps some of the most challenging areas 
for protecting the privacy of health information [92–94]. Recently, development makes it pos-
sible to learn a great deal about disease processes and individual variations in treatment effec-
tiveness or susceptibility to disease from genetic analyses as the DNA sequences comprising 
a person’s genome strongly influence a person’s health.
Human genome knowledge, combined with advances in computing capabilities, can help 
decipher the roles that genetics and the environment play in the origins of complex but com-
mon human diseases as cancer. Patient samples stored in bio-specimen banks can provide 
a wealth of information for addressing long-standing questions about health and disease, 
and efforts are underway to create large genomic databases for that purpose [74, 94]. These 
data are of paramount importance for any community that could affect the national security. 
Based on the strict privacy rules inside the European Union than the United States, DNA is 
not direct identifier in Europe [95].
Genetic information does not itself identify an individual in the absence of other identifying 
information. Person’s genetic code could be interpreted as a unique identifier and used to 
match a sequence in another databank, which includes identifiers [96, 97].
The NIH starts requiring data from the Genome-Wide Association Study in January 2008. 
That database became publicly accessible until August 2008 then NIH removed the database 
from the public Website regarding patient privacy [95, 98]. Those concerns stemmed from a 
study showing that a new type of DNA analysis could confirm the identity of an individual in 
a pool of similarly masked data if that person’s genetic profile was already known [99]. NIH 
intends to move the aggregate genotype data to a secure, controlled-access database with 
policies for review and approval of data access requests in very strict manner [98].
5. International ethical standards in medical research
5.1. History and legal basis of research ethics
Research ethics is mostly developed as a concept in medical research, but the general prin-
ciples apply for all fields of research. Informed consent and confidentiality are important for 
both sociological study and clinical research keeping both human and patient rights. As a 
reaction to malpractices that were revealed during the Nuremberg trials, the World Medical 
Association (established in Paris in 1947) adopted the DH in 1964, in Finland [100].
The DH stated that “for all research, the well-being of the individuals is the most important over 
all other interests and sets principles for medical research combined with medical care” [60].
5.2. The Nuremberg Code
The Nuremberg Code was the first international code of ethics for research on human sub-
jects, introduced in 1947 after WWII, when the Nazi’s outrageous experiments on human 
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subjects were revealed to the world. The Nuremberg Code focused on medical research, con-
sisting of only 10 rules which indicated the most basic and essential principles [101]. In fact, 
the Nuremberg Code has had a major influence on human rights law and medical ethics. 
In contrast, while the previous ethics codes focused on the obligations of the investigator 
toward the research subjects, the Nuremberg Code reverses that logic: The rights are directly 
awarded to the research subjects who is actually revolute to the view on research ethics [102].
5.3. The Declaration of Helsinki (DH)
The World Medical Association (WMA) introduced the DH in 1964 to provide additional 
guidance for researchers beyond what was included in the Nuremberg Code [103]. Hence, the 
Declaration is longer and more detailed (37 articles) than the Nuremberg Code (10 articles). 
Since the publication of the DH, it has been amended nine times, most recently in October 
2013 [104]. The DH is considered the best-known and most widely available guideline in 
medical research ethics [104].
The DH covers a broad assortment of topics such as privacy and confidentiality, research 
oversight, protocol development, protection of vulnerable subjects, publication, scientific 
design, the use of placebos, and access to treatments [104]. In many countries, the HD has 
been enacted as law (such as the Nuremberg Code in some U.S. courts), and adherence to its 
principles is a requirement of many national and international guidelines [105].
5.4. International Ethical Guidance from the Council for International Organizations of 
Medical Sciences (CIOMS)
The CIOMS was formally constituted by the WHO and the United Nations Educational, 
Scientific, and Cultural Organization (UNESCO) in 1949, and it still remains under the aegis 
of these two specialized UN agencies. In 1982, CIOMS proposed the International Ethical 
Guidelines for Biomedical Research Involving Human Subjects. The purpose of these guide-
lines was to indicate how the ethical principles that were set forth in the 1975 version of 
the DH could be effectively applied. Emphasis was on application in developing countries, 
given their socioeconomic circumstances, laws, regulations, and executive and administrative 
arrangements. The guidelines were revised in 1993 and in 2002 [106]. The CIOMS guidelines 
are more detailed than the DH. They consist of 21 articles with many commentaries for each 
article which explain in detail many different situations. The CIOMS guidelines have had 
covered the topics of ethical justification and scientific validity of research, ethical review 
committees, informed consent registration, susceptibility of individuals, risk/benefits rela-
tionship, choice of control in clinical trials, privacy, compensation for injury in research, and 
national capacity to provide healthcare services [107].
In the meanwhile, the agreement on Human Rights and Biomedicine or the Oviedo 
Convention, adopted by the Ministers of the Council of Europe in 1996, stated that there is 
a strong connection between research ethics and human rights [108–110]. Including the pri-
macy of the interest and human well-being, informed consent, and privacy are the corners 
of the research. The agreement sets standards for the use of the human genome and human 
embryos research [111].
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UNESCO’s Universal Declaration on Bioethics and Human Rights and CIOMS International 
Ethical Guidelines for Biomedical Research Involving Human Subjects are all other important 
international declarations and agreement [112, 113].
Within the European regulatory framework, research ethics is based on the evident European 
commitment to human rights. Firmly enshrined in the treaties, compliance with human rights 
is fundamental for all European policy domains [114].
5.5. Informed consent and conflict of obligations
Informed consent constitutes the cornerstone of research ethics in human subjects. It is the 
most important to recognize that there are differences between informed consent for partici-
pation in research and informed consent for patient care. Its importance is to unravel the gray 
zone especially in vulnerable groups [115, 116].
A great problem occurred when the doctor is both the investigator and the provider of patient 
care [115, 116], especially in developing countries where it may be impossible to separate 
the roles of investigator and care giver. In this case, the conflict of interest in many occa-
sions could be obvious concerning that in developing countries grossly inadequate health 
care resources and the pressures to enroll research subjects may concentrate more on patients’ 
best interests [117].
Informed consent is basic requirement in research involving human being, research, genetic 
material or biological samples, and data collection. The rights and interests of the research 
subjects are fully respected especially during children research [117, 118], vulnerable adults 
(elderly, prisoners, mentally deficient persons, comatose, severely injured patients, and psy-
chiatric patients), and people with certain cultural, religious, or traditional backgrounds [118].
There are various requirements for a valid informed consent that must be fulfilled, such as 
the four requirements that Jennifer S. Hawking explains per her quotation: “First, only those 
potential subjects who pass the requirements for decision-making competence should be 
asked to give consent (when it is necessary to enroll incompetent subjects an appropriate sur-
rogate must give consent). Second, there must be full disclosure of all the relevant information, 
Third, the subject or surrogate must understand the information, and Fourth, he or she must 
then consent freely or voluntarily” [119].
Shamoo and Resnik specify three challenges of acquiring informed consent in developing 
countries. First, there is the possible presence of linguistic barriers that might make it difficult 
to acquire effective consent. It can be necessary to use interpreters in order to converse with 
subjects in their native language and translations of consent documents, and other material 
such as brochures, questionnaires, and visual aid must be produced. Some words may not 
translate easily into different languages which may affect interpretation of the text presented 
to the subjects. Furthermore, some populations may have no written language, so use of a 
consent form or other such document can be problematic [77]. The second challenge is that 
there can be conceptual or cultural obstacles to effective consent. People from developing 
and unindustrialized countries may have little comprehension of Western concepts such as 
disease, cause and effect, genetics/DNA, virus, bacteria, and so on.
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In order to assure that the requirement of full understanding is met, it is necessary to adapt 
the form and content of procedures for obtaining informed consent to the educational level 
of the potential subjects of research [78]. Third and last, many African nations consist of tribal 
governance. The leaders of the tribe may need to give permission before any member of the 
tribe can be recruited into a study and the members may not believe they have any right 
to decide by themselves whether to participate or not. They may not even comprehend the 
notion of individual decision [77].
Ethical relativists have used cultural differences, like lack of understanding of the concept 
“individual consent,” as a defense for departing from widely accepted ethical standards for 
informed consent. Furthermore, in developing countries, women are sometimes thought of 
as less than men and their husbands sometimes make all the decisions, even those that only 
affect their wife’s health and her enrolment in medical studies [78].
5.6. Animal research ethics
In Europe, the Commission report estimates that over 12 million animals are used for experimen-
tal or other scientific purposes each year. The most common used animals for these  purposes 
are rodents, rabbits, mice, and rats [120].
The European Convention for the Protection of Vertebrate Animals used for Experimental 
and Other Scientific Purposes, adopted in 1986, is the first important document protecting 
the animals used in experiments [114]. This directive since its application in 1986 is meant to 
ensure the protection of animals used in experiments or for other scientific purposes and sets 
standards for control on the use of laboratory animals, housing and care of the animals, and 
for the training of the personnel involved in the animal testing [114]. Apart from setting stan-
dards, the directive aims at reducing the numbers of animals used for experiments, following 
the concept of the “Three R’s (replacement, reduction, and refinement).”
For the Ethics Review organized by the European Commission, the researcher should provide 
all the details of the species (and strains) used, justify why they are used, explain why the 
anticipated benefits of the research justify the use of animals, and why methods avoiding the 
use of animals cannot be used [114, 115]. National authorities are responsible for the imple-
mentation of the Directive on the Protection of Animals [114].
5.7. Twelve golden rules to ethical research conduct
According to the 12 golden rules, each researcher must ensure that his/her research will fulfill 
the following criteria [114, 121]:
Respects the persons before, during, and after the research, follow the “Do no harm” principle, 
realize the rights of individuals to privacy, personal data protection and freedom of movement, 
informed consent for human being research, treat animals with respect following the three Rs: 
Replacement, Reduction, and Refinement when designing animal research, never misuse terror-
ists or military organizations, respect integrity of an individual and that any modification (genetic 
or technological) does not interfere with this principle, always respect environment biodiversity, 
and finally build on the understanding that any benefits are for the good of the society [122–124].




The need for new and better treatment options for medical research continues unabated. As long 
as that need persists, medical trials are likely to continue. Many medical researches are driven 
by economic or academic interests that may or may not reflect the needs of the host country.
The pharmaceutical industry is not a charitable business but it is a profitable one. There 
are many reasons that attract these companies, researchers, and sponsors to conduct their 
research in a developing country.
Many moral lessons have been learnt from the history of medical research. Regrettably, 50 
years after the Nuremberg trials and the Nuremberg Code, unethical medical research on 
humans continues.
Protecting patients involved in research from harm or abuse and preserving their rights is 
essential to ethical research. Human rights, health development, and medical research ethics 
can be gathered together when standards are followed with minimizing bias and conflict of 
interests. Informed consent and confidentiality are important for both sociological study and 
clinical research keeping both human and patient rights.
Human and animal rights should be preserved in all categories of medical research. Quality 
of research in the medical field will be reflected on the quality of health care and welfare of 
the community whether it is performed in developing or developed countries. The 3 R’s: 
Replacement, Reduction, and Refinement have to be followed. International guidelines pro-
vided by WHO, DH, CIOMS, WMA, UNESCO, and Nuremberg Code need to be ascertained 
in research whether performed in developed or developing countries. Most, but not all devel-
oping countries, have ethical review committees in the form of research institutes or other 
scientific panels. However, the reality is that these panels need to be independent and able to 
review clinical trials without prejudice.
We do not want a scientifically neat study if it is ethically flawed, we need to redouble our 
commitment to the highest ethical standards, no matter where the research is conducted, and 
sponsoring agencies need to enforce those standards.
The Tanta experience can be taken as a role model in developing countries to initiate guide-
lines to standardize the ethics of medical research at national and regional levels.
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